Details of Disease

General Information of Disease (ID: DIS6KF0Q)

• Disease Name: Haemophilia B
• Disease Class: 3B11: Christmas disease
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS6KF0Q: Haemophilia B
• ICD Code:
  ICD-11: ICD-11: 3B11.0
  ICD-9: ICD-9: 286.1
  Expand ICD-11: '3B11.0
  Expand ICD-9: 286.1
• Disease Identifiers:
  MONDO ID: MONDO_0010604
  MESH ID: D002836
  UMLS CUI: C0008533
  OMIM ID: 306900
  MedGen ID: 945
  Orphanet ID: 98879
  SNOMED CT ID: 41788008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Coagulation Factor IX	DM8HBJI	Approved	NA	[1]
Recombinant factor IX-Fc	DM533MX	Approved	NA	[2]

This Disease is Treated as An Indication in 12 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AMT-061	DMSO02K	Phase 3	Gene therapy	[3]
Concizumab	DM1BRWD	Phase 3	Monoclonal antibody	[4]
Fidanacogene elaparvovec	DMFZ81T	Phase 3	Gene therapy	[5]
Nonocog beta pegol	DM9FKEE	Phase 3	NA	[6]
OPK88005	DMGETGH	Phase 2	NA	[7]
AAV5-hFIXco	DMNQMAP	Phase 1/2	NA	[6]
AskBio009	DMDUPBV	Phase 1/2	NA	[8]
BAX335	DM7GJ9Z	Phase 1/2	NA	[6]
DTX101	DM4766H	Phase 1/2	NA	[6]
SB-FIX	DMUP52Y	Phase 1/2	Gene therapy	[9]
SPK-FIX	DMI4BGD	Phase 1/2	NA	[6]
ALN-AT3SC	DMMO9I4	Phase 1	NA	[6]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [2] Clinical pipeline report, company report or official report of Biogen idec.
• [3] ClinicalTrials.gov (NCT03569891) HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT05135559) Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors. U.S.National Institutes of Health.
• [5] ClinicalTrials.gov (NCT03861273) A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2). U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of OPKO Health
• [8] ClinicalTrials.gov (NCT01687608) Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health.